Lyell Immunopharma, Inc. (NASDAQ:LYEL) Given Consensus Recommendation of “Moderate Buy” by Analysts

Shares of Lyell Immunopharma, Inc. (NASDAQ:LYEL) have been given an average recommendation of “Moderate Buy” by the six analysts that are currently covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, three have given a buy rating and one has given a strong buy rating to the company. The average 12 month price target among analysts that have issued ratings on the stock in the last year is $43.00.

A number of equities analysts have issued reports on LYEL shares. Citizens Jmp started coverage on shares of Lyell Immunopharma in a research report on Monday, March 9th. They set a “market outperform” rating and a $34.00 target price for the company. Robert W. Baird set a $49.00 price objective on shares of Lyell Immunopharma and gave the company an “outperform” rating in a research report on Thursday, April 30th. Needham & Company LLC reissued a “buy” rating and issued a $44.00 price objective on shares of Lyell Immunopharma in a research report on Thursday, May 7th. Wall Street Zen raised shares of Lyell Immunopharma from a “sell” rating to a “hold” rating in a research report on Sunday, May 10th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Lyell Immunopharma in a research report on Tuesday, April 21st.

Hedge Funds Weigh In On Lyell Immunopharma

Several institutional investors and hedge funds have recently bought and sold shares of the stock. GSK plc purchased a new stake in Lyell Immunopharma during the fourth quarter worth approximately $46,560,000. MWG Caph Ltd acquired a new stake in Lyell Immunopharma during the 4th quarter valued at $31,030,000. ARCH Venture Management LLC grew its holdings in Lyell Immunopharma by 51.5% during the 3rd quarter. ARCH Venture Management LLC now owns 2,759,072 shares of the company’s stock valued at $44,807,000 after purchasing an additional 938,438 shares in the last quarter. Acadian Asset Management LLC grew its holdings in Lyell Immunopharma by 204.2% during the 1st quarter. Acadian Asset Management LLC now owns 660,899 shares of the company’s stock valued at $354,000 after purchasing an additional 443,614 shares in the last quarter. Finally, Vanguard Group Inc. boosted its stake in Lyell Immunopharma by 76.0% during the 3rd quarter. Vanguard Group Inc. now owns 779,004 shares of the company’s stock valued at $12,651,000 after acquiring an additional 336,378 shares during the last quarter. Institutional investors and hedge funds own 66.05% of the company’s stock.

Lyell Immunopharma Trading Up 3.0%

LYEL stock opened at $17.33 on Friday. The company has a market cap of $404.31 million, a P/E ratio of -1.26 and a beta of -0.05. Lyell Immunopharma has a 52 week low of $7.65 and a 52 week high of $45.00. The company’s 50-day moving average price is $20.46 and its 200 day moving average price is $23.54.

Lyell Immunopharma (NASDAQ:LYEL) last released its quarterly earnings data on Wednesday, May 6th. The company reported ($1.10) EPS for the quarter, hitting analysts’ consensus estimates of ($1.10). The firm had revenue of $0.00 million for the quarter, compared to the consensus estimate of $0.00 million. Lyell Immunopharma had a negative net margin of 794,858.12% and a negative return on equity of 85.71%. On average, equities research analysts expect that Lyell Immunopharma will post -8.37 earnings per share for the current year.

About Lyell Immunopharma

Lyell Immunopharma is a clinical-stage biotechnology company focused on developing next-generation T cell therapies for cancer. Leveraging a proprietary platform that combines cell therapy, gene editing and molecular discovery, Lyell seeks to overcome key barriers in the treatment of solid tumors. The company’s approach centers on engineering T cells to enhance their persistence, functionality and resistance to the immunosuppressive tumor microenvironment.

The company’s pipeline includes multiple autologous T cell programs engineered to target tumor-associated antigens in solid malignancies such as melanoma, ovarian and pancreatic cancers.